SCHEMBL3268039

SCHEMBL3268039

O=C1NCc2c1c1c(c3[nH]c4ccc(Br)cc4c23)Cc2ccccc2-1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K9 P80192 9/20 0.76
MAP3K11 Q16584 9/20 0.76
PRKCA P17252 5/20 0.76
KDR P35968 4/20 0.76
PRKCQ Q04759 4/20 0.76
PRKCD Q05655 4/20 0.76
MAP3K10 Q02779 3/20 0.76
PRKD3 O94806 3/20 0.76
PRKCG P05129 3/20 0.76
PRKCB P05771 3/20 0.76
PRKCH P24723 3/20 0.76
PRKCI P41743 3/20 0.76
PRKCE Q02156 3/20 0.76
PRKCZ Q05513 3/20 0.76
PRKD1 Q15139 3/20 0.76
NTRK1 P04629 2/20 0.76
PARP1 P09874 4/20 0.63
ROCK2 O75116 4/20 0.49
MAP3K5 Q99683 2/20 0.49
IKBKB O14920 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6629443 0.87 MAP3K9 (0.76) MAP3K9MAP3K11PRKCAKDRPRKCQ
SCHEMBL3072275 0.87 MAP3K11 (1.00) MAP3K9MAP3K11PRKCAKDRPRKCQ
SCHEMBL3268623 0.85 MAP3K9 (0.73) MAP3K9MAP3K11PRKCAKDRPRKCQ
SCHEMBL6629885 0.85 CDK4 (0.63) MAP3K9MAP3K11PRKCAKDRPRKCQ
SCHEMBL14494184 0.85 MAP3K9 (0.72) MAP3K9MAP3K11PRKCAKDRPRKCQ
SCHEMBL14494154 0.85 KDR (0.74) MAP3K9MAP3K11PRKCAKDRPRKCQ
SCHEMBL14494163 0.83 MAP3K9 (0.69) MAP3K9MAP3K11PRKCAKDRPRKCQ
SCHEMBL14494166 0.81 KDR (0.69) MAP3K9MAP3K11PRKCAKDRPRKCQ
SCHEMBL14510328 0.81 KDR (0.67) MAP3K9MAP3K11PRKCAKDRPRKCQ
SCHEMBL14494156 0.81 KDR (0.79) MAP3K9MAP3K11PRKCAKDRPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383813-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2013-02-26 US disclosed
US-20120004253-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2012-01-05 US disclosed
US-8044064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-10-25 US disclosed
US-8044064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-10-25 US disclosed
US-20100152196-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2010-06-17 US disclosed
US-20100152196-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2010-06-17 US disclosed
US-7671064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2010-03-02 US disclosed
US-7671064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2010-03-02 US disclosed
US-7169802-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-01-30 US disclosed
US-7169802-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152196-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 MAP3K9 3651/4885MAP3K11 3535/4885PRKCA 2189/4885
US-20120004253-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 MAP3K9 3651/4885MAP3K11 3535/4885PRKCA 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.